Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy.

MacNeil, Ian A; Khan, Salmaan A; Sen, Adrish; Soltani, Sajjad M; Burns, David J; Sullivan, Brian F; Laing, Lance G

MacNeil, Ian A; Khan, Salmaan A; Sen, Adrish; Soltani, Sajjad M; Burns, David J; Sullivan, Brian F; Laing, Lance G.

Afiliação

MacNeil IA; Celcuity, Inc., 16305 36th Ave N, Suite 100, Minneapolis, MN, 55446, USA.
Khan SA; Celcuity, Inc., 16305 36th Ave N, Suite 100, Minneapolis, MN, 55446, USA.
Sen A; Celcuity, Inc., 16305 36th Ave N, Suite 100, Minneapolis, MN, 55446, USA.
Soltani SM; Celcuity, Inc., 16305 36th Ave N, Suite 100, Minneapolis, MN, 55446, USA.
Burns DJ; Celcuity, Inc., 16305 36th Ave N, Suite 100, Minneapolis, MN, 55446, USA.
Sullivan BF; Celcuity, Inc., 16305 36th Ave N, Suite 100, Minneapolis, MN, 55446, USA.
Laing LG; Celcuity, Inc., 16305 36th Ave N, Suite 100, Minneapolis, MN, 55446, USA. LLaing@Celcuity.com.

Cell Commun Signal ; 20(1): 4, 2022 01 08.

Article em En | MEDLINE | ID: mdl-34998412

Assuntos

Neoplasias da Mama; Animais; Neoplasias da Mama/patologia; Linhagem Celular Tumoral; Feminino; Humanos; Camundongos; Receptor ErbB-2/metabolismo; Transdução de Sinais; Microambiente Tumoral

Palavras-chave

Combination targeted therapy; Dysfunctional signaling; HER; c-Met

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google